WO2000008195A1 - Procede et dispositif de transfert d'oligonucleotides dans des cellules - Google Patents
Procede et dispositif de transfert d'oligonucleotides dans des cellules Download PDFInfo
- Publication number
- WO2000008195A1 WO2000008195A1 PCT/DE1999/002327 DE9902327W WO0008195A1 WO 2000008195 A1 WO2000008195 A1 WO 2000008195A1 DE 9902327 W DE9902327 W DE 9902327W WO 0008195 A1 WO0008195 A1 WO 0008195A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oligonucleotides
- transferred
- cell
- cells
- shock wave
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 41
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims description 18
- 230000035939 shock Effects 0.000 claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims description 38
- 239000007788 liquid Substances 0.000 claims description 14
- 230000003834 intracellular effect Effects 0.000 claims description 6
- 210000000170 cell membrane Anatomy 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
- C12M35/04—Mechanical means, e.g. sonic waves, stretching forces, pressure or shear stimuli
Definitions
- the invention relates to a method for intracellular transfer of oligonucleotides according to method claim 1 and a device for carrying out the method according to device claim 4
- oligonucleotides The intracellular transfer of oligonucleotides is used to specifically inhibit the synthesis of individual proteins in the cell.
- a short-chain synthetic nucleic acid with a freely selectable sequence of bases is introduced into the cytoplasm of the cell as soon as the cell nucleus of the cell is used to synthesize a If the so-called mRNA, which is necessary for the protein, is released, the oligonucleotide in the cell can take the place of the mRNA, the sequence of which is complementary to the base sequence of the gonucleotide.
- This “application” blocks the synthesis of exactly one protein. This cell is therefore absent an otherwise present protein The absence of this protein can result in a change in the cell's properties or mortality
- carrier lipids are used, by means of which an improvement in the uptake of the gonucleotides into the cytoplasm of the cell is produced.
- a disadvantage of this known method is the need for these relatively expensive carrier lipids in addition to the Having to apply oligonucleotides as consumable for intracellular transfer
- Another known possibility of transferring oligonucleotides provides for direct introduction, for example by means of microinjections or electroporation.
- direct introduction for example by means of microinjections or electroporation.
- the effectiveness of the method of direct introduction is disadvantageous
- cavitation occurs in liquids under the influence of shock waves.
- This cavitation can be represented simply as the formation and movement of bubbles or cavities in a liquid.
- a very fine, needle-like liquid jet is formed. This liquid jet penetrates the cell membrane and transfers a small amount of the liquid into the cell.
- Oligonucleotides there is a probability, depending on the concentration of the oligonucleotides in the liquid, that oligonucleotides have been transferred into the cell.
- FIG. 1 shows a schematic structure of a device 1 with which the method according to the invention can be carried out.
- the device 1 is filled with a liquid 2.
- the liquid 2 can be exposed to a shock wave by means of a shock wave generator 3.
- a sample container 4 is partially immersed in the liquid 2.
- the sample container 4 is attached to a holder, not shown for reasons of clarity.
- This solution 5 contains the oligonucleotides and the target cells into which the oligonucleotides are to be transferred.
- the material of the sample container 4 is continuous for shock waves, the essentially aqueous solution 5 in which the oligonucleotides and the target cells for the transfer of the oligonucleotides also pass on the shock waves.
- Fluid jet hits the cell, it penetrates the cell membrane like a microinjection. A small amount of the liquid that makes up the fluid jet remains in the cell.
- the oligonucleotides to be transferred are stochastically distributed in the liquid, the oligonucleotides are also transferred stochastically to individual cells.
- Activating the shock wave source several times increases the probability that oligonucleotides will be transferred into the cell.
- the target cells can be in a living being, and the oligonucleotides can be located near the target cells by suitable measures (such as blood circulation or injection) Extracorporeal shock waves in the body of the living being and focusing on the one area of the body in which the target cells are located, it is possible to introduce locally limited oligonucleotides into cells of the body and thus change the properties of the cells and / or their mortality or lethality.
- suitable measures such as blood circulation or injection
- shock wave source for the purpose of transferring oligonucleotides in cells both in vivo and in vitro represents a method in which harmful influences on the cells, for example through the currents during electroporation or side effects caused by the carrier lipids, are advantageously avoided.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Mechanical Engineering (AREA)
- Cell Biology (AREA)
- Sustainable Development (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Des oligonucléotides sont transférés dans des cellules par l'action d'ondes de choc.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU63241/99A AU6324199A (en) | 1998-07-31 | 1999-07-30 | Method and device for the transfer of oligonucleotides in cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19834612A DE19834612A1 (de) | 1998-07-31 | 1998-07-31 | Verfahren zum intrazellulären Transfer von Oligonukleotiden und Vorrichtung zur Durchführung desselben |
DE19834612.3 | 1998-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000008195A1 true WO2000008195A1 (fr) | 2000-02-17 |
Family
ID=7876022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1999/002327 WO2000008195A1 (fr) | 1998-07-31 | 1999-07-30 | Procede et dispositif de transfert d'oligonucleotides dans des cellules |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU6324199A (fr) |
DE (1) | DE19834612A1 (fr) |
WO (1) | WO2000008195A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001048181A3 (fr) * | 1999-12-23 | 2002-04-18 | Dornier Medizintechnik | Procede pour transferer des molecules dans des cellules |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10223196B4 (de) * | 2002-05-24 | 2004-05-13 | Dornier Medtech Systems Gmbh | Verfahren und Einrichtung zum Transferieren von Molekülen in Zellen |
WO2020085281A1 (fr) * | 2018-10-26 | 2020-04-30 | 国立大学法人九州大学 | Procédé de projection de bulles, dispositif de projection de bulles et appareil de projection de bulles |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0137504A2 (fr) * | 1983-10-13 | 1985-04-17 | Rikagaku Kenkyusho | Méthode et appareil pour implanter une substance étrangère dans des cellules vivantes |
US4750100A (en) * | 1986-06-06 | 1988-06-07 | Bio-Rad Laboratories | Transfection high voltage controller |
WO1989002464A1 (fr) * | 1987-09-07 | 1989-03-23 | Amersham International Plc | Modification de cellules vivantes |
WO1991000358A1 (fr) * | 1989-06-29 | 1991-01-10 | Danisco A/S | Procede d'introduction de molecules, notamment de matiere genetique, dans des cellules vegetales |
US5098843A (en) * | 1987-06-04 | 1992-03-24 | Calvin Noel M | Apparatus for the high efficiency transformation of living cells |
EP0506632A2 (fr) * | 1991-03-28 | 1992-09-30 | Ente per le nuove tecnologie, l'energia e l'ambiente ( ENEA) | Microporation par laser |
WO1994009145A1 (fr) * | 1992-10-13 | 1994-04-28 | Cangene Corporation | Transfection de particucles: procede de transfert de molecules polynucleotidiques dans des cellules |
WO1997040679A1 (fr) * | 1996-05-01 | 1997-11-06 | Imarx Pharmaceutical Corp. | Procedes d'apport de composes dans une cellule |
US5753477A (en) * | 1996-03-19 | 1998-05-19 | University Technology Corporation | Magneto-biolistic methods |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL92529A0 (en) * | 1989-12-03 | 1990-08-31 | Yissum Res Dev Co | Generation of transgenic vertebrates by employing transformed sperm cells via artificial insemination |
US5766901A (en) * | 1995-05-04 | 1998-06-16 | The Board Of Trustees Of The Leland Stanford Junior University | Apparatus and method for delivering a nucleotide into cell nuclei |
-
1998
- 1998-07-31 DE DE19834612A patent/DE19834612A1/de not_active Ceased
-
1999
- 1999-07-30 WO PCT/DE1999/002327 patent/WO2000008195A1/fr active Application Filing
- 1999-07-30 AU AU63241/99A patent/AU6324199A/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0137504A2 (fr) * | 1983-10-13 | 1985-04-17 | Rikagaku Kenkyusho | Méthode et appareil pour implanter une substance étrangère dans des cellules vivantes |
US4750100A (en) * | 1986-06-06 | 1988-06-07 | Bio-Rad Laboratories | Transfection high voltage controller |
US5098843A (en) * | 1987-06-04 | 1992-03-24 | Calvin Noel M | Apparatus for the high efficiency transformation of living cells |
WO1989002464A1 (fr) * | 1987-09-07 | 1989-03-23 | Amersham International Plc | Modification de cellules vivantes |
WO1991000358A1 (fr) * | 1989-06-29 | 1991-01-10 | Danisco A/S | Procede d'introduction de molecules, notamment de matiere genetique, dans des cellules vegetales |
EP0506632A2 (fr) * | 1991-03-28 | 1992-09-30 | Ente per le nuove tecnologie, l'energia e l'ambiente ( ENEA) | Microporation par laser |
WO1994009145A1 (fr) * | 1992-10-13 | 1994-04-28 | Cangene Corporation | Transfection de particucles: procede de transfert de molecules polynucleotidiques dans des cellules |
US5753477A (en) * | 1996-03-19 | 1998-05-19 | University Technology Corporation | Magneto-biolistic methods |
WO1997040679A1 (fr) * | 1996-05-01 | 1997-11-06 | Imarx Pharmaceutical Corp. | Procedes d'apport de composes dans une cellule |
Non-Patent Citations (3)
Title |
---|
BAO ET AL.: "In Vivo Transfection of Melanoma Cells by Lithotripter Shock Waves", CANCER RES., vol. 58, 15 January 1998 (1998-01-15), pages 219 - 221, XP002125162 * |
DELIUS ET AL.: "Extracorporeal shock waves for gene therapy?", LANCET, vol. 345, 27 May 1995 (1995-05-27), pages 1377, XP002125161 * |
LAUER ET AL.: "Shock wave permeabilization as a new gene transfer system in vitro.", J. CELL. BIOCHEM. SUPPL., vol. 0, no. 21A, 1995, pages 396, XP002125160 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001048181A3 (fr) * | 1999-12-23 | 2002-04-18 | Dornier Medizintechnik | Procede pour transferer des molecules dans des cellules |
Also Published As
Publication number | Publication date |
---|---|
AU6324199A (en) | 2000-02-28 |
DE19834612A1 (de) | 2000-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE19752585B4 (de) | Vorrichtung und Verfahren zum Verkapseln von mikrobiellen, pflanzlichen und tierischen Zellen bzw. von biologischen und chemischen Substanzen | |
Nansen | The structure and combination of the histological elements of the central nervous system | |
DE69518437T2 (de) | Verfahren zur herstellung transformierter zellen | |
DE3855330T2 (de) | Verfahren zur zellpermeabilisierung und zellfusion unter verwendung elektrischer radiofrequenz impulse | |
McGUINNESS et al. | The afferent projections to the centrum medianum of the cat as demonstrated by retrograde transport of horseradish peroxidase | |
DE3214667C2 (de) | Zusammengesetzter Körper für die Langzeitabgabe von Wirkstoffen | |
DE69533474T2 (de) | Gerät und methode für die effiziente inkorporation von molekülen in zellen | |
DE69534348T2 (de) | Gasbetätigtes Element zum Austragen von Genmaterial | |
DE60007290T2 (de) | Einbringen von makromolekülen in zellen | |
DE69633725T2 (de) | Kationische lipide/dns komplexe zum zielen von genen | |
DE69031951T2 (de) | Transformation von tierischen Hautzellen mit hilfe von Partikeln | |
DE60212941T2 (de) | Verfahren zur übertragung ausgewählter moleküle | |
WO2003035868A1 (fr) | Medicament qui augmente l'efficacite d'un remede declenchant l'apoptose mediee par recepteur dans des cellules tumorales | |
CH653914A5 (de) | Verfahren zum einkapseln eines chemisch aktiven kernmaterials. | |
EP1325122A2 (fr) | Modulation de la transcription de produits geniques pro-inflammatoires | |
Scharfman | Epileptogenesis in the parahippocampal region: parallels with the dentate gyrus | |
WO2000008195A1 (fr) | Procede et dispositif de transfert d'oligonucleotides dans des cellules | |
DE3710371A1 (de) | Zerstoerung von krankhaft veraenderten gewebezellen | |
Rubinson | The central distribution of VIII nerve afferents in larval Petromyzon marinus | |
DE3321226C2 (de) | Verfahren zur Fusion von Zellen | |
Yin et al. | Effects of axotomy on lamprey spinal neurons | |
Garrod | Cellular development | |
Kageyama et al. | Dense HRP filling in pre-fixed brain tissue for light and electron microscopy. | |
Bernardo et al. | In vitro labeling of axonal projections in the mammalian central nervous system | |
EP0681834B1 (fr) | Microcapsule, ainsi qu'un procédé et un appareil pour la produire |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 1999 63241 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR JP SG US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |